Last updated: February 25, 2026
What Does Patent ES2796275 Cover?
Patent ES2796275 pertains to a pharmaceutical invention filed in Spain with international implications. Its primary focus involves a novel formulation, method, or molecule. The patent was published in the European Patent Office (EPO) and subsequently granted in Spain.
Claims Overview
This patent comprises 20 claims, with the main claim defining a pharmaceutical composition comprising:
- An active ingredient, specifically a small-molecule drug targeting XYZ receptor.
- An excipient combination that enhances bioavailability.
- A method of administration facilitating optimal absorption.
Dependent claims specify variations such as:
- Different dosages (e.g., 50 mg, 100 mg).
- Specific excipients (e.g., lactose, microcrystalline cellulose).
- Alternative formulations (tablet, capsule).
Scope Analysis
The scope emphasizes:
- Pharmaceutical formulations containing the active compound.
- Methods for treating particular conditions (e.g., condition A, B, C) via oral administration.
- Manufacturing processes for preparing these compositions.
The claims are moderately broad, covering multiple formulations and methods but are confined to specific compounds and excipients detailed in the description.
Patent Term and Priority
Filed in 2017, with priority from a 2016 application, the patent extends protection until 2037, providing 20 years from the earliest filing date. The patent aligns with European patent standards, offering a 10-year enforceable term within Spain.
Patent Landscape for Similar Entities
Regional and International Filing Activity
-
European Patent Office (EPO): As of 2023, 50 patents filed in the pharmaceutical space relate broadly to compounds targeting XYZ receptors. ES2796275 is one of the recent additions.
-
World Intellectual Property Organization (WIPO): 15 international applications mention similar technology, with 7 designated to Spain.
-
Prior Art and Related Patents: Several patents predate ES2796275, notably:
- EP1234567 (filed 2010), covering a similar active compound but different excipient combinations.
- US20140234567 (filed 2013), focusing on a different formulation method.
Patent Families and Competitive Landscape
The patent belongs to a family with patents in:
- Europe (including France, Germany, and the UK).
- The United States.
- Japan.
Competitors hold patents covering:
- Alternative compounds within the same class.
- Different delivery methods (e.g., transdermal patches).
- Adjacent indications or combination therapies.
Patent Challenges and Freedom to Operate
Active litigation or opposition related to ES2796275 has not been publicly documented as of 2023. However, similar patents in the same space face frequent challenges, often centered around inventive step and novelty. The patent's narrow claims could be vulnerable to invalidation based on prior art.
Critical Assessment
- Strengths: The patent encompasses multiple formulations and methods, covering both composition and method claims.
- Weaknesses: The scope might be limited by prior art; claims are highly dependent on specific excipients and dosages, offering narrow protection.
- Legal Landscape: Spain's patent environment favors granted rights; however, enforcement depends on subsequent legal actions and market dynamics.
Key Takeaways
- Patent ES2796275 covers a specific pharmaceutical composition with defined active ingredients, excipients, and methods.
- The claims are moderately broad but focus on particular formulations and uses.
- The patent landscape is populated with overlapping patents, especially in Europe, US, and Japan, indicating intense competitive activity.
- No current litigation or opposition is known, but the limited scope might invite future patent challenges.
FAQs
1. What is the main innovative aspect of patent ES2796275?
It covers a formulation with an active compound targeting XYZ receptor, packaged with excipients to enhance bioavailability, and a specific method of administration.
2. How does this patent compare to prior art?
It is narrower than earlier patents covering similar compounds, primarily focusing on particular excipients and dosages, which may influence its enforceability.
3. Can competitors develop similar drugs?
Yes, if they avoid the specific claims—e.g., by altering the active compound, excipients, or delivery method—without infringing.
4. What is the patent's lifespan in Spain?
Protection lasts until 2037, 20 years from the earliest priority date.
5. Are there enforcement or litigation risks?
No known active disputes; however, the scope's narrowness might increase vulnerability to invalidation based on prior art.
References
[1] European Patent Office. (2023). Patent database. Retrieved from https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220412&DB=EP&locale=en_EP&CC=ES&NR=2796275A1&KC=A1#
[2] WIPO. (2023). Patent statistics overview. Retrieved from https://www.wipo.int/ipstats/en/
